TenX Keane Acquisition
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TENK and buy or sell other stocks, ETFs, and their options commission-free!About TENK
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
CEOLeonard L. Mazur, MBA
CEOLeonard L. Mazur, MBA
Employees—
Employees—
HeadquartersCranford, New Jersey
HeadquartersCranford, New Jersey
Founded
Founded
Employees—
Employees—
TENK Key Statistics
Market cap80.85M
Market cap80.85M
Price-Earnings ratio-5.93
Price-Earnings ratio-5.93
Dividend yield—
Dividend yield—
Average volume992.35K
Average volume992.35K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$6.19
52 Week high$6.19
52 Week low$0.5506
52 Week low$0.5506
Stock Snapshot
The current TenX Keane Acquisition(TENK) stock price is $1.13, with a market capitalization of 80.85M. The stock trades at a price-to-earnings (P/E) ratio of -5.93.
During the trading day, TenX Keane Acquisition(TENK) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for TenX Keane Acquisition(TENK) stock has reached 0, versus its average volume of 992.35K.
Over the past 52 weeks, TenX Keane Acquisition(TENK) stock has traded between a high of $6.19 and a low of $0.55.
Over the past 52 weeks, TenX Keane Acquisition(TENK) stock has traded between a high of $6.19 and a low of $0.55.
People also own
Based on the portfolios of people who own TENK. This list is generated using Robinhood data, and it’s not a recommendation.